RecruitingPhase 1NCT07465835

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

Sponsor

Electra Therapeutics Inc.

Enrollment

84 participants

Start Date

Feb 17, 2026

Study Type

INTERVENTIONAL

Conditions

T-cell Malignancies

Summary

This is a Phase 1, two-part, multicenter study to evaluate ELA026 in participants ≥18 years old with relapsed/refractory TCM following any line of prior therapy who are eligible for investigational treatments.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Age ≥18 years Participants with a confirmed histologic diagnosis of a TCM who are R/R following any line of prior therapy (participants with CTCLs should have received at least 2 prior lines of systemic therapy for R/R CTCL) and eligible for investigational therapies
Presence of measurable disease by clinical examination, radiologic imaging (computed tomography, magnetic resonance imaging, or whole body FDG-PET scans), and/or in bone marrow aspirate/biopsy
Eastern Cooperative Oncology Group performance score of ≤2
Anticipated life expectancy \>6 months per investigator judgment

Exclusion Criteria7

Participants who are eligible for standard of care or approved therapeutic options for R/R TCMs with established clinical benefit
Organ dysfunction as defined in the protocol
Participants with hemophagocytic lymphohistiocytosis (HLH) based on HLH2004 diagnostic criteria
Participants receiving or planning to start immunotherapy or immune effector cell therapy (such as chimeric antigen receptor \[CAR\] T-cell therapy, T-cell engagers, or programmed cell death protein 1 \[PD1\]/programmed cell death ligand 1 \[PD-L1\] inhibitors)
Allogeneic hemopoietic stem cell transplant within 100 days prior to the first dose of ELA026 and currently receiving systemic immunosuppressive therapy
Women of childbearing potential who are planning to become pregnant or are breastfeeding during the conduct of the study, including 60 days after last dose of study drug
Male participants whose partners are women of childbearing potential and who are planning to become pregnant during the conduct of this trial by the male partner, including within 60 days after the last dose of study drug